FDA Grants Accelerated Approval to J&J's ENHANZE-Based RYBREVANT FASPRO in Head and Neck Cancer
HALO sits 80% above its 52-week low of $61.225 on light trading volume (0.4× avg).
Summary
Johnson & Johnson won FDA accelerated approval for RYBREVANT FASPRO, co-formulated with Halozyme's ENHANZE, as a single agent in recurrent or metastatic head and neck squamous cell carcinoma that progressed after platinum-based chemo and an anti-PD-(L)1 antibody. It is the first dual-targeted EGFR/MET therapy approved in this setting, and the label excludes HPV-associated oropharyngeal disease. Halozyme earns royalties on partner product sales, so a new indication widens the revenue base for its highest-profile ENHANZE asset beyond lung cancer, though Halozyme projects zero to minimal royalty impact through 2035 and no projected impact on its ability to execute new ENHANZE partnership agreements. The approval lands a day after Halozyme posted Q3 revenue of $493.0M (+39%) and raised full-year 2026 guidance, reinforcing the royalty growth story. Size the impact as incremental rather than transformative — HNSCC is a smaller population than the lung cancer indications, and J&J books the product revenue while Halozyme collects a royalty rate.
At the time of this announcement, HALO was trading at $110.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.5B. The 52-week trading range was $61.23 to $134.00. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: PR Newswire.